Search for content, post, videos

Spago Nanomedical initiates clinical trial in endometriosis

spago nanomedical
Spago Nanomedical has received regulatory approval to initiate a Phase IIa clinical study with its MRI contrast agent SN132D in endometriosis. Patient recruitment has started, and the first patient is expected to be dosed shortly. The ongoing SPAGOPIX-01 study in breast cancer has now been conclu
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.